Thermal Dosimetry Analysis Combined with Patient-specific Thermal Modeling of Clinical Interstitial Ultrasound Hyperthermia Integrated within HDR Brachytherapy for Treatment of Locally Advanced Prostate Cancer

Salgaonkar, Vasant A.; Wootton, Jeff; Prakash, Punit; Scott, Serena; Hsu, I. C.; Diederich, Chris J.
April 2017
AIP Conference Proceedings;2017, Vol. 1821 Issue 1, p1
Conference Proceeding
This study presents thermal dosimetry analysis from clinical treatments where ultrasound hyperthermia (HT) was administered following high-dose rate (HDR) brachytherapy treatment for locally advanced prostate cancer as part of a clinical pilot study. HT was administered using ultrasound applicators from within multiple 13-g brachytherapy catheters implanted along the posterior periphery of the prostate. The heating applicators were linear arrays of sectored tubular transducers (~7 MHz), with independently powered array elements enabling energy deposition with 3D spatial control. Typical heat treatments employed time-averaged peak acoustic intensities of 1 - 3 W/cm2 and lasted for 60 - 70 minutes. Throughout the treatments, temperatures at multiple points were monitored using multi-junction thermocouples, placed within available brachytherapy catheters throughout mid-gland prostate and identified as the hyperthermia target volume (HTV). Clinical constraints allowed placement of 8 - 12 thermocouple sensors in the HTV and patient-specific 3D thermal modeling based on finite element methods (FEM) was used to supplement limited thermometry. Patient anatomy, heating device positions, orientations, and thermometry junction locations were obtained from patient CT scans and HDR and hyperthermia planning software. The numerical models utilized the applied power levels recorded during the treatments. Tissue properties such as perfusion and acoustic absorption were varied within physiological ranges such that squared-errors between measured and simulated temperatures were minimized. This data-fitting was utilized for 6 HT treatments to estimate volumetric temperature distributions achieved in the HTV and surrounding anatomy devoid of thermocouples. For these treatments, the measured and simulated T50 values in the hyperthermia target volume (HTV) were between 40.1 - 43.9 °C and 40.3 - 44.9 °C, respectively. Maximum temperatures between 46.8 - 49.8 °C were measured during these treatments and the corresponding range obtained from simulation was 47.3 - 51.1 °C. Based on the simulations, the maximum temperatures in the bladder and the rectum were below 41.7 °C and 41.1 °C, respectively.


Related Articles

  • Be it resolved that in the modern era, the best method for dose escalation is brachytherapy: The con position. Loblaw, D. Andrew // Canadian Urological Association Journal;Jun2012, Vol. 6 Issue 3, p199 

    The author discusses how increase in the dose of radiation therapy can affect the treatment of prostate cancer. He informs that external beam radiotherapy dose when given in accurate and precise way can give better outcomes and can lower cost and also mentions that brachytherapy is a safe method...

  • Focal therapy in prostate cancer: the current situation. Jácome-Pita, F. X.; Sánchez-Salas, R.; Barret, E.; Amaruch, N.; Gonzalez-Enguita, C.; Cathelineau, X. // Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1 

    Prostate cancer is one of the most significant pathologies in the field of urology. The adoption of screening strategies and improvements in biopsies have resulted in an increase in early-stage tumour detection. Radical global therapies provide very good oncological results in localised prostate...

  • Post-Brachytherapy Erectile Function Is Preserved in Most PCa Patients.  // Renal & Urology News;Sep2014, Vol. 13 Issue 9, p15 

    The article presents a study led by Jeremy L. Millar, associate professor of surgery and public health at Monash University in Melbourne, Victoria, about the impact of permanent seed brachytherapy (BT) on patients with localized prostate cancer (PCa). The study found that three-fifths of PCa...

  • Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: A prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study.  // Radiation Oncology;2012, Vol. 7 Issue 1, p24 

    The article offers information on the study conducted by the authors related to gold marker displacement due to needle insertion during high-dose-rate (HDR)-brachytherapy for treatment of prostate cancer. It states that HDR-brachytherapy is a highly precise option in prostate cancer treatment to...

  • Personal preferences and discordant prostate cancer treatment choice in an intervention trial of men newly diagnosed with localized prostate cancer. Bosco, Jaclyn L. F.; Halpenny, Barbara; Berry, Donna L. // Health & Quality of Life Outcomes;2012, Vol. 10 Issue 1, p123 

    Background: Men diagnosed with localized prostate cancer (LPC) can choose from multiple treatment regimens and are faced with a decision in which medical factors and personal preferences are important. The Personal Patient Profile-Prostate (P3P) is a computerized decision aid for men with LPC...

  • The best method for dose escalation: Prostate brachytherapy. Morton, Gerard // Canadian Urological Association Journal;Jun2012, Vol. 6 Issue 3, p196 

    The author discusses the role of radiation therapy dose in the treatment of prostate cancer. He informs that external beam radiotherapy dose increases the biochemical control rate to about 10 percent in five years and also mentions that brachytherapy is a safe method of dose escalation. He...

  • Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherapy. da Silva Franca, Carlos Antônio; Vieira, Sérgio Lannes; Carvalho, Antonio Carlos Pires; Bernabe, Antonio Jose Serrano; Penna, Antonio Belmiro Rodrigues Campbell // Radiologia Brasileira;Mar/Apr2014, Vol. 47 Issue 2, p89 

    Objective: To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods: In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The...

  • Quality of life after prostate cancer treatments in patients comparable at baseline. van Tol-Geerdink, J J; Leer, J W H; van Oort, I M; van Lin, E J N T; Weijerman, P C; Vergunst, H; Witjes, J A; Stalmeier, P F M // British Journal of Cancer;5/14/2013, Vol. 108 Issue 9, p1784 

    Background:Previous studies on the effects of different prostate cancer treatments on quality of life, were confounded because patients were not comparable. This study examined treatment effects in more comparable groups.Methods:From 2008-2011, 240 patients with localised prostate cancer were...

  • Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer. Osmonov, Daniar K.; Aksenov, Alexey V.; Boller, Annkathrin; Kalz, Almut; Heimann, Diana; Janssen, Isa; Jünemann, Klaus-Peter // Advances in Urology;2014, p1 

    Background. Treatment of patients with a biochemical recurrence (BCR) of prostate cancer (PCa) is generally difficult and without valid treatment options. Since 2004 we have been developing therapeutic possibilities for these patients. Methods. We retrospectively analyzed a cohort of 41 patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics